Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

IFN-Gamma Signature Not Linked to Durvalumab/Tremelimumab Benefit in Gastric Cancer

Brandon Scalea
Published: Monday, Apr 22, 2019

eoffrey Y. Ku, MD

Geoffrey Y. Ku, MD

Although prospective screening with an RNA-based interferon (IFN)-γ gene expression signature proved feasible for selecting patients with gastric cancer who would most benefit from the combination of durvalumab (Imfinzi) and tremelimumab, use of this signature failed to lead to a significant improvement in clinical outcomes, said Geoffrey Y. Ku, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication